Screener
Recursion Pharmaceuticals, Inc. RXRX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $1,212,668 | $1,474,130 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $12,672 | $18,118 |
| Accrued expenses and other liabilities | 56,936 | 70,230 |
| Unearned revenue | 27,586 | 37,605 |
| Operating lease liabilities | 13,249 | 12,663 |
| Notes payable and financing lease liabilities | 9,443 | 9,091 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s accounts payable?
- Recursion Pharmaceuticals, Inc. (RXRX) reported accounts payable of $12.67M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s accounts payable changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s accounts payable decreased by 34.4% year-over-year, from $19.31M to $12.67M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s accounts payable?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s accounts payable has grown at a 49.1% compound annual growth rate (CAGR), from $15.47M to $76.45M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Recursion Pharmaceuticals, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude